A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study
Post date: Oct 11, 2015 9:57:17 AM
The INFLOW was a prospective, noninterventional study assessing the effectiveness and safety of long-acting bronchodilators in patients with COPD from the Middle East, Asia, and South Africa. Patients newly prescribed or switched to indacaterol or other long-acting β2-agonist (LABA), or tiotropium (monotherapy or in combination) were evaluated over 6 months. The primary endpoint was the clinical COPD questionnaire overall score at the end of the study.
The authors conclude that in real life clinical practice across a diverse region, indacaterol and other long-acting bronchodilators improved health status and were well regarded by patients and physicians.